Article
Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy.
Surgery - 1 Nov 2015
Valsangkar Nakul, Sehdev Amikar, Misra Subhasis, Zimmers Teresa A, O'Neil Bert H, Koniaris Leonidas G
Abstract excerpt
In the past decade, the addition of molecular diagnosis of mutations and use of tyrosine kinase inhibitors (TKIs), either as neoadjuvant/adjuvant therapy with surgery or as primary therapy in nonresectable gastrointestinal stromal tumors (GIST), has improved patient outcomes markedly. Additional therapeutics also are on the horizon. The goal of this review is to identify the current incidence, diagnostic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.